KPTI Stock Performance, Insider Transaction and News

KPTI - Karyopharm Therapeutics Inc.

Market Cap	204.08M	P/E	-	EPS this Y	1.60%	Ern Qtrly Grth	-
Income	-143.1M	Forward P/E	-2.01	EPS next Y	17.90%	50D Avg Chg	-8.00%
Sales	146.03M	PEG	0.04	EPS past 5Y	-	200D Avg Chg	-46.00%
Dividend	N/A	Price/Book	N/A	EPS next 5Y	-30.30%	52W High Chg	-70.00%
Recommedations	1.90	Quick Ratio	3.16	Shares Outstanding	115.07M	52W Low Chg	24.00%
Insider Own	5.99%	ROA	-27.05%	Shares Float	105.16M	Beta	0.06
Inst Own	67.41%	ROE	-	Shares Shorted/Prior	22.95M/23.44M	Price	1.79
Gross Margin	96.62%	Profit Margin	-97.99%	Avg. Volume	3,435,614	Target Price	5.57
Oper. Margin	-112.03%	Earnings Date	May 2	Volume	2,225,002	Change	-0.56%

Healthcare | Biotechnology | United States

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Karyopharm Therapeutics Inc. News

04/01/24	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/06/24	Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
03/04/24	Insider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...
03/01/24	Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call Transcript
02/29/24	Q4 2023 Karyopharm Therapeutics Inc Earnings Call
02/29/24	Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript
02/29/24	Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
02/29/24	Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
02/25/24	7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
02/22/24	Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
02/19/24	Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?
02/15/24	Ardelyx (ARDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
02/14/24	Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should Know
02/07/24	Karyopharm Therapeutics (NASDAQ:KPTI) adds US$104m to market cap in the past 7 days, though investors from three years ago are still down 90%
01/08/24	Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
01/03/24	Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
12/10/23	Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)
12/06/23	Great week for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) institutional investors after losing 84% over the previous year
11/08/23	Karyopharm to Participate at Upcoming Investor Conferences
11/06/23	Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study

KPTI Chatroom

celebratelife Posted - 23 minutes ago

$KPTI The man responsible for burning through millions of shareholder funds, destroying shareholder value, catered free daily lunch and other perks to the benefit of the insiders. Richard Paulson.

PrettyBlob Posted - 1 hour ago

$KPTI Holy fuck totally wrecked. Shorts own this sack of shit stock. Thanks for all your support keeping the share price high, mgmt!! The only way to beat shorty here is to… Sell. The. Company.

mich1282 Posted - 8 hours ago

$KPTI https://www.fiercepharma.com/pharma/fda-advisers-back-new-endpoint-myeloma-approvals-paving-way-faster-introduction-new-drugs

DoctorDueDiligence Posted - 22 hours ago

$KPTI Shareholder vote letter to the Chairman of the Board Barry Greene https://twitter.com/DueDoctor/status/1780000255251185884

longrigger52 Posted - 1 day ago

$KPTI pos have 2 say it

ekpemofolo Posted - 1 day ago

$KPTI It finally spoke, thank god!

PrettyBlob Posted - 1 day ago

$KPTI Looks like we’re going to have to start worrying about sub-$1 compliance soon… Leave it to this clueless mgmt team to cock up a brilliant bullish chart opportunity - broke all the bullish patterns and currently sliced through all support. Great work protecting the share price y‘all! Sell. The. Company.

longrigger52 Posted - 3 days ago

$KPTI a six month gig

jster Posted - 4 days ago

$KPTI blob? you ok? no post yet??

Watson66 Posted - 4 days ago

$KPTI I guess it’s on: https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-begins-tender-offer-morphosys-2024-04-11/

longrigger52 Posted - 4 days ago

$KPTI cafe pharma had some interesting viewpoints over there today some think tht no way is bp interested in kpti a d that their ”potential” rev stream is not real. also, that if they thiught it was real, they would have taken the cimpany out on the cheap and not have to pay 3 b fir Mor i guess time will tell

jster Posted - 4 days ago

$KPTI there's some abnormal AH movement on this one today. I hope that means what I think it means

PrettyBlob Posted - 6 days ago

$KPTI Lost the larger triangle tracing out since Feb, dropped out of the smaller ascending triangle over the last 4-5 days, struggling to get back to 50dma… someone call life support! Seriously, every single potential bullish pattern opportunity this stock has had have broken down. Masterful dastardly complete domination by shorts… with nothing from the company except a tired lukewarm investor presentation goven time and time again, and news across the wores of the CEO’s share sales 😏 Sell. The. Company.

lllIIIII Posted - 6 days ago

$KPTI Over 60% tutes ownership for what was essentially a penny stock? Big pharma wants confirmation. Accelerate the trial or die from dilution. Bad management, good science. Typical biotech.

seforim Posted - 6 days ago

$KPTI Canaccord Genuity Horizons in Oncology Conference, April 15 RBC Capital Markets Global Healthcare Conference May 14-15 ASCO MAY 31 - JUNE 4

TickerDD_com Posted - 1 week ago

From 3/22/2024, looking back across 22 Month-Ends for KPTI, Percentage Change of Average Monthly Price had Equal (50%) while Percentage Change of Average Monthly Volume had All Positives (100%) $KPTI #KPTI #KPTIStock #TickerDD https://www.youtube.com/watch?v=nsS4HzGAEu8

everydayCPA Posted - 1 week ago

$KPTI snoozing until this breaks out of the flag…

Notyouraverage_shark Posted - 1 week ago

$KPTI

AlexPEC Posted - 1 week ago

$KPTI https://thepatientstory.com/patient-events/myelofibrosis-patient-events/clinical-trials-sept-23/

seforim Posted - 1 week ago

$KPTI https://www.reddit.com/r/KPTI/s/g2vGT13Bdh

seforim Posted - 1 week ago

$KPTI https://x.com/kinatsofrim/status/1777459899569426825

seforim Posted - 1 week ago

$KPTI https://m.youtube.com/watch?v=GISX5MHya28

DoctorDueDiligence Posted - 1 week ago

$KPTI

Gius_me Posted - 1 week ago

$KPTI they temporary fixed at least one financial problem..waiting for the maturity debt…meh 🫤

Idvst8 Posted - 1 week ago

$KPTI - gotta be a buy at some point ?!??!?!? unreal price action since 2020. Booooooo

AlexPEC Posted - 1 week ago

$KPTI Trust experts, or blob?

GreenNGold22 Posted - 1 week ago

$KPTI Am I reading this right…1.5 b in debt?

GreenNGold22 Posted - 1 week ago

$KPTI Going to take a starter here.

insiderbuyingselling Posted - 1 week ago

$KPTI new insider selling: 3563 shares. http://insiderbuyingselling.com/?t=KPTI

seforim Posted - 1 week ago

$KPTI Cantor Fitzgerald has Karyopharm #13 on list for b/o https://www.investing.com/news/stock-market-news/biotech-ripe-for-cascade-of-dealmaking--here-are-the-top-companies-to-watch-3365129

Analyst Ratings

HC Wainwright & Co.	Buy	Mar 1, 24
Piper Sandler	Overweight	Nov 3, 23
RBC Capital	Outperform	Nov 3, 23
Morgan Stanley	Equal-Weight	Aug 7, 23
Piper Sandler	Overweight	Aug 3, 23
RBC Capital	Outperform	Aug 3, 23
HC Wainwright & Co.	Buy	Aug 3, 23
Wedbush	Neutral	Jul 26, 23
HC Wainwright & Co.	Buy	Jul 26, 23

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
Paulson Richard A.	President and CEO President and CEO	Jan 04	Sell	0.82	4,114	3,373	783,465	01/08/24
Paulson Richard A.	President and CEO President and CEO	Dec 04	Sell	0.79	3,622	2,861	787,579	12/05/23
Paulson Richard A.	President and CEO President and CEO	Nov 06	Sell	0.9203	3,606	3,319	791,201	11/07/23
Paulson Richard A.	President and CEO President and CEO	Oct 04	Sell	1.27	3,589	4,558	794,807	10/05/23
BOHLIN GAREN G	Director Director	Sep 12	Buy	1.215	41,140	49,985	45,140	09/12/23
Paulson Richard A.	President and CEO President and CEO	Aug 07	Sell	1.72	3,722	6,402	802,018	08/08/23
Poulton Stuart	EVP, Chief Developme.. EVP, Chief Development Officer	Jul 28	Sell	1.70	2,845	4,836	156,286	08/01/23
Paulson Richard A.	President and CEO President and CEO	Jul 05	Sell	1.72	3,538	6,085	805,740	07/06/23
Rangwala Reshma	EVP & Chief Medical.. EVP & Chief Medical Officer	Apr 20	Sell	4.04	6,770	27,351	158,230	04/24/23
Paulson Richard A.	President and CEO President and CEO	Apr 04	Sell	3.97	3,497	13,883	816,619	04/05/23
Mason Michael	EVP, CFO & Treasurer EVP, CFO & Treasurer	Feb 28	Sell	3.03	11,205	33,951	245,361	03/02/23
Paulson Richard A.	President and CEO President and CEO	Feb 28	Sell	3.03	33,033	100,090	823,622	03/02/23
Paulson Richard A.	President and CEO President and CEO	Dec 05	Sell	5.17	3,490	18,043	612,527	12/06/22
Paulson Richard A.	President and CEO President and CEO	Nov 04	Sell	4.54	3,493	15,858	616,017	11/08/22
Paulson Richard A.	President and CEO President and CEO	Sep 08	Sell	5.24	3,479	18,230	622,998	09/09/22
Greene Barry E	Director Director	Aug 11	Option	1.485	7,576	11,250	13,606	08/15/22
Cheng Sohanya Roshan	Chief Commercial Off.. Chief Commercial Officer	Jun 13	Sell	5.27	1,551	8,174	89,949	06/14/22
PAKIANATHAN DEEPIKA	Director Director	Jun 08	Sell	6.23	538,784	3,356,624	16,673	06/10/22
Paulson Richard A.	President and CEO President and CEO	Jun 07	Sell	5.7602	2,542	14,642	630,906	06/08/22
Mason Michael	EVP, CFO, Treasurer EVP, CFO, Treasurer	Jun 03	Sell	6.05	601	3,636	138,509	06/06/22
Shacham Sharon	Chief Scientific Off.. Chief Scientific Officer	Feb 28	Sell	10.24	12,452	127,508	713,757	03/02/22
Kauffman Michael	Director Director	Feb 28	Sell	10.24	12,452	127,508	898,131	03/02/22
Kauffman Michael	Director Director	Feb 17	Sell	12.12	18,167	220,184	904,357	02/22/22
Shah Jatin	EVP, Chief Medical O.. EVP, Chief Medical Officer	Feb 07	Sell	9.862	1,704	16,805	130,756	02/09/22
Frenkel Ran	EVP, Chief Dev. Offi.. EVP, Chief Dev. Officer	Feb 07	Sell	9.862	1,991	19,635	104,632	02/09/22
Mason Michael	EVP, CFO & Treasurer EVP, CFO & Treasurer	Feb 07	Sell	9.862	3,947	38,925	53,308	02/09/22
Kauffman Michael	Director Director	Feb 07	Sell	9.86	13,471	132,824	913,445	02/09/22
Shacham Sharon	Chief Scientific Off.. Chief Scientific Officer	Feb 07	Sell	9.86	13,471	132,824	708,062	02/09/22
Shacham Sharon	President & CSO President & CSO	Feb 22	Sell	14.83	18,990	281,622	575,126	02/22/21
Shah Jatin	EVP, Chief Medical O.. EVP, Chief Medical Officer	Feb 17	Sell	15.52	1,748	27,129	48,127	02/17/21
Frenkel Ran	EVP, Chief Dev. Offi.. EVP, Chief Dev. Officer	Feb 17	Sell	15.52	2,046	31,754	39,338	02/17/21
Kauffman Michael	Chief Executive Offi.. Chief Executive Officer	Feb 17	Sell	15.52	13,243	205,531	764,147	02/17/21
Mirza Mansoor Raza	Director Director	Dec 22	Sell	18	5,000	90,000		12/22/20
Mirza Mansoor Raza	Director Director	Dec 22	Option	5.43	5,000	27,150	5,000	12/22/20
Lewis Tanya	EVP,Chief Reg.&Quali.. EVP,Chief Reg.&Quality Officer	Nov 04	Sell	15.58	226	3,521	539	11/04/20
Shah Jatin	EVP, Chief Medical O.. EVP, Chief Medical Officer	Nov 04	Sell	19.46	589	11,462	43,229	11/04/20
Primiano Christopher Brett	EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary	Oct 14	Option	9.8	39,271	384,856	5,370	10/14/20
Primiano Christopher Brett	EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary	Oct 14	Sell	17.03	39,271	668,785	4,649	10/14/20
Kauffman Michael	Chief Executive Offi.. Chief Executive Officer	Oct 14	Option	0.03	7,500	225	763,989	10/14/20
Kauffman Michael	Chief Executive Offi.. Chief Executive Officer	Oct 14	Sell	14.89	7,500	111,675	756,489	10/14/20
Shacham Sharon	President & CSO President & CSO	Oct 14	Option	0.03	7,500	225	763,989	10/14/20
Shacham Sharon	President & CSO President & CSO	Oct 14	Sell	14.89	7,500	111,675	756,489	10/14/20
Primiano Christopher Brett	EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary	Sep 10	Option	6.54	10,054	65,753	14,703	09/10/20
Primiano Christopher Brett	EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary	Sep 10	Sell	14.98	10,054	150,609	4,649	09/10/20